Juan Camilo Villada Valencia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Camilo Villada Valencia has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Linares-Ballesteros
Fundación Hospital Pediátrico La Misericordia Bogotá D.C. Colombia
1 shared publication - Diana Constanza Plazas Hernández
Universidad Nacional de Colombia, Universidad Nacional de Colombia, Facultad de Medicina, Departamento de Pediatría, Bogotá, Colombia, 2 Fundación Hospital Pediátrico de la Misericordia-HOMI, Oncohematología pediátrica, Bogotá Colombia
1 shared publication - Iván Perdomo Ramírez
Fundación Hospital Pediátrico de la Misericordia-HOMI, Unidad Cuidado Intensivo pediátrico, Bogotá Colombia
1 shared publication - Nelson Hernando Aponte Barrios
HOMI Fundación Hospital Pediátrico la Misericordia
1 shared publication - Oscar Guillermo Arévalo-Leal
Fundación Hospital Pediátrico La Misericordia, Colombia
1 shared publication - Roy Sanguino Lobo
Fundación Hospital Pediátrico La Misericordia, Colombia
1 shared publication
Latest Publications
- Open Access
- 30 January 2021
- Published by Universidad del Valle in Colombia Medica
- Vol. 52 (1) , e2034542
Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
Background: Acute leukemias are the most frequent malignancies in children. Advances in treatment have improved the overall survival to 80%. Almost 10% of children with cancer develop clinical cardiac toxicity. Total anthracycline cumulative dose is a risk factor for early-onset cardiotoxicity. Objective: To describe the incidence of early-onset cardiotoxicity in children with acute leukemia treated with chemotherapy. Methods: A prospective descriptive study of patients >1 y and 150 mg/m2, between the first echocardiographic evaluation and posterior analyses in the left ventricular fraction ejection with Teicholz p 0.05, Simpson p 0.018 and GLS p 0.004. In this study, there was no relation between blood biomarkers and cardiotoxicity. Conclusions: Cancer therapeutic-related cardiac dysfunction is related to anthracycline cumulative dose. In this study, echocardiographic follow-up was useful to predict risk factors for early cardiac dysfunction.
- 30 January 2021
- Published by Universidad del Valle in Colombia Medica
- Vol. 52 (1) , e2034542
Open AccessEarly-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
Background: Acute leukemias are the most frequent malignancies in children. Advances in treatment have improved the overall survival to 80%. Almost 10% of children with cancer develop clinical cardiac toxicity. Total anthracycline cumulative dose is a risk factor for early-onset cardiotoxicity. Objective: To describe the incidence of early-onset cardiotoxicity in children with acute leukemia treated with chemotherapy. Methods: A prospective descriptive study of patients >1 y and 150 mg/m2, between the first echocardiographic evaluation and posterior analyses in the left ventricular fraction ejection with Teicholz p 0.05, Simpson p 0.018 and GLS p 0.004. In this study, there was no relation between blood biomarkers and cardiotoxicity. Conclusions: Cancer therapeutic-related cardiac dysfunction is related to anthracycline cumulative dose. In this study, echocardiographic follow-up was useful to predict risk factors for early cardiac dysfunction.